Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bruna Velosa Ferreira has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina João

    Hemato-Oncology Unit, Fundação Champalimaud, 1400-038 Lisbon, Portugal

    8 shared publications
  • Emilie Arnault Carneiro

    Myeloma Lymphoma Research Group-Champalimaud Experimental Clinical Research Programme of Champalimaud Foundation, Lisbon 1400-038, Portugal

    6 shared publications
  • Raquel Lopes

    Myeloma Lymphoma Research Group-Champalimaud Experimental Clinical Research Programme of Champalimaud Foundation, Lisbon 1400-038, Portugal; Faculty of Medicine, University of Lisbon, Lisbon 1649-028, Portugal

    5 shared publications
  • Filipa Barahona

    Myeloma Lymphoma Research Group-Champalimaud Experimental Clinical Research Programme of Champalimaud Foundation, Lisbon 1400-038, Portugal; NOVA Medical School, NOVA University, Lisbon, Lisbon 1169-056, Portugal

    3 shared publications
  • Bruno Costa-Silva

    Systems Oncology Group, Champalimaud Centre for the Unknown

    2 shared publications
  • Bruno Costa-Silva

    Systems Oncology Group, Champalimaud Research, Champalimaud Centre for the Unknown, Av. Brasília, 1400-038 Lisbon, Portugal

    2 shared publications

Latest Publications

  • Open Access

    Size-Exclusion Chromatography: A Path to Higher Yield and Reproducibility Compared to Sucrose Cushion Ultracentrifugation for Extracellular Vesicle Isolation in Multiple Myeloma

    by Madalena Grenhas, Raquel Lopes, Bruna Velosa Ferreira, Filipa Barahona, Cristina João, Emilie Arnault Carneiro

    Small extracellular vesicles (EVs) play a pivotal role in intercellular communication across various physiological and pathological contexts. Despite their growing significance as disease biomarkers and therapeutic targets in biomedical research, the lack of reliable isolation techniques remains challenging. This study characterizes vesicles that were isolated from conditioned culture media (CCM) sourced from three myeloma cell lines (MM.1S, ANBL-6, and ALMC-1), and from the plasma of healthy donors and multiple myeloma patients. We compared the efficacy, reproducibility, and specificity of isolating small EVs using sucrose cushion ultracentrifugation (sUC) vs. ultrafiltration combined with size-exclusion chromatography (UF-SEC). Our results demonstrate that UF-SEC emerges as a more practical, efficient, and consistent method for EV isolation, outperforming sUC in the yield of EV recovery and exhibiting lower variability. Additionally, the comparison of EV characteristics among the three myeloma cell lines revealed distinct biomarker profiles. Finally, our results suggest that HBS associated with Tween 20 improves EV recovery and preservation over PBS. Standardization of small EV isolation methods is imperative, and our comparative evaluation represents a significant step toward achieving this goal.


  • Open Access

    Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment

    by Raquel Lopes, Joana Caetano, Filipa Barahona, Carolina Pestana, Bruna Velosa Ferreira, Diana Lourenço, Ana C. Queirós, Carlos Bilreiro, Noam Shemesh, Hans Christian Beck, et al.

    Multiple myeloma (MM), the third most frequent hematological cancer worldwide, is characterized by the proliferation of neoplastic plasma cells in the bone marrow (BM). One of the hallmarks of MM is a permissive BM microenvironment. Increasing evidence suggests that cell-to-cell communication between myeloma and immune cellsviatumor cell-derived extracellular vesicles (EV) plays a key role in the pathogenesis of MM. Hence, we aimed to explore BM immune alterations induced by MM-derived EV. For this, we inoculated immunocompetent BALB/cByJ mice with a myeloma cell line, MOPC315.BM, inducing a MM phenotype. Upon tumor establishment, characterization of the BM microenvironment revealed the expression of both activation and suppressive markers by lymphocytes, such as granzyme B and PD-1, respectively. In addition, conditioning of the animals with MOPC315.BM-derived EV, before transplantation of the MOPC315.BM tumor cells, did not anticipate the disease phenotype. However, it induced features of suppression in the BM milieu, such as an increase in PD-1 expression by CD4+ T cells. Overall, our findings reveal the involvement of MOPC315.BM-derived EV protein content as promoters of immune niche remodeling, strengthening the importance of assessing the mechanisms by which MM may impact the immune microenvironment.


  • Open Access

    Boosting Immunity against Multiple Myeloma

    by Raquel Lopes, Bruna Velosa Ferreira, Joana Caetano, Filipa Barahona, Emilie Arnault Carneiro, Cristina João

    Despite the improvement of patient’s outcome obtained by the current use of immunomodulatory drugs, proteasome inhibitors or anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. More recently, the testing in clinical trials of novel drugs such as anti-BCMA CAR-T cells, antibody–drug conjugates or bispecific antibodies broadened the possibility of improving patients’ survival. However, thus far, these treatment strategies have not been able to steadily eliminate all malignant cells, and the aim has been to induce a long-term complete response with minimal residual disease (MRD)-negative status. In this sense, approaches that target not only myeloma cells but also the surrounding microenvironment are promising strategies to achieve a sustained MRD negativity with prolonged survival. This review provides an overview of current and future strategies used for immunomodulation of MM focusing on the impact on bone marrow (BM) immunome.


  • Open Access

    The Immune Microenvironment in Multiple Myeloma: Friend or Foe?

    by Raquel Lopes, Joana Caetano, Bruna Ferreira, Filipa Barahona, Emilie Arnault Carneiro, Cristina João

    Multiple myeloma (MM) is one of the most prevalent hematological cancers worldwide, characterized by the clonal expansion of neoplastic plasma cells in the bone marrow (BM). A combination of factors is implicated in disease progression, including BM immune microenvironment changes. Increasing evidence suggests that the disruption of immunological processes responsible for myeloma control ultimately leads to the escape from immune surveillance and resistance to immune effector function, resulting in an active form of myeloma. In fact, one of the hallmarks of MM is the development of a permissive BM milieu that provides a growth advantage to the malignant cells. Consequently, a better understanding of how myeloma cells interact with the BM niche compartments and disrupt the immune homeostasis is of utmost importance to develop more effective treatments. This review focuses on the most up-to-date knowledge regarding microenvironment-related mechanisms behind MM immune evasion and suppression, as well as promising molecules that are currently under pre-clinical tests targeting immune populations.


  • Open Access

    Liquid biopsies for multiple myeloma in a time of precision medicine

    by Bruna Ferreira, Joana Caetano, Filipa Barahona, Raquel Lopes, Emilie Carneiro, Bruno Costa-Silva, Cristina João

    Multiple myeloma (MM) is a challenging, progressive, and highly heterogeneous hematological malignancy. MM is characterized by multifocal proliferation of neoplastic plasma cells in the bone marrow (BM) and sometimes in extramedullary organs. Despite the availability of novel drugs and the longer median overall survival, some patients survive more than 10 years while others die rapidly. This heterogeneity is mainly driven by biological characteristics of MM cells, including genetic abnormalities. Disease progressions are mainly due to the inability of drugs to overcome refractory disease and inevitable drug-resistant relapse. In clinical practice, a bone marrow biopsy, mostly performed in one site, is still used to access the genetics of MM. However, BM biopsy use is limited by its invasive nature and by often not accurately reflecting the mutational profile of MM. Recent insights into the genetic landscape of MM provide a valuable opportunity to implement precision medicine approaches aiming to enable better patient profiling and selection of targeted therapies. In this review, we explore the use of the emerging field of liquid biopsies in myeloma patients considering current unmet medical needs, such as assessing the dynamic mutational landscape of myeloma, early predictors of treatment response, and a less invasive response monitoring.


  • Open Access

    PS1364 EXOSOMAL CARGO IN MONOCLONAL GAMMOPATHIES COMPARED TO HEALTHY DONORS AND ITS POTENTIAL RELATION TO MYELOMA AGGRESSIVENESS

    by B. Ferreira, E. Carneiro, F. Barahona, P. Lucio, M. Neves, B. Costa‐Silva, C. Joao

  • Multiple myeloma patients-derived exosomes as a potential new clinical tool

    by Bruna Ferreira, Paulo Lúcio, Manuel Neves, António Parreira, Bruno Costa-Silva, Cristina João

    Introduction: Multiple Myeloma (MM) is a highly heterogeneous neoplasia, usually preceded by a monoclonal-gammopathy-of-undetermined-significance (MGUS). MM has a diverse clinical presentation, variable response to treatment and outcome. Poor response to novel drugs or extramedullary-disease (EMD) are some of the parameters associated to poor prognosis. Exosomes (EXO) are extracellular vesicles implicated, among others, in promotion of supportive tumor microenvironments [ 1 Costa-Silva B , Aiello NM , Ocean AJ , et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;7(6):816–826. [Google Scholar] ]. EXO in MM may act as biomarkers of disease aggressiveness [ 2 Manier S , Avet-Loiseau H , Campigotto F , et al. Circulating exosomal microRNAs are critical prognostic markers independent of cytogenetics and International Staging System in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. [Internet]. 2015;15:e47–e48. doi:10.1016/j.clml.2015.07.183 [Crossref], [PubMed] , [Google Scholar] ] and potentially be used as “liquid biopsies” for better stratification of disease. Materials and methods: EXO were isolated from peripheral blood (PB) and bone marrow (BM) patient samples by sequential ultracentrifugation. Patient (MM, MGUS) and healthy donors (HD) were compared regarding EXO concentration (EXO/ml) and average protein cargo/EXO (µg/EXO), in PB and BM. Informed consent of the subjects and acceptance of the study protocol by a local ethics committee has been obtained. µg/EXO was determined by the ratio between total quantity of EXO proteins, measured by protein assay using bicinchoninic acid, and the total number of exosomes, measured by Nanosight. Statistical analysis was done with GraphPad. Results: There was no difference in EXO/ml in MM vs MGUS vs HD. However, a positive correlation in EXO/ml between PB and BM in MM and MGUS (Pearson R = 0.80; p < 0.0001) was found. MM patients (n = 10) had 2,8x more µg/EXO in PB, when compared to MGUS patients (n = 5) (p = 0.058); MM median 1.2 (0.50–3.33) µg/EXO versus MGUS median 0.43 (0.10–0.69) µg/EXO. In BM, µg/EXO was also 2,6x higher in MM than in MGUS: 0.92 (0.15–2.13) µg/EXO versus 0.36 (0.06–0.45) µg/EXO, respectively. Analyzing patients by clinical subgroups, we found that those with EMD had higher µg/EXO. Comparing µg/EXO pre-treatment (T1) and at response evaluation (T2), we found that patients with progressive disease had a lower decrease (48%) when compared to patients achieving response to treatment (90%): median T1 1.24 (1.12–3.45) µg/EXO and median T2 0.65 (0.5–0.72) µg/EXO vs median T1 3.29 (1.17–4.15) µg/EXO and median T2 0.35 (0.32–0.5) µg/EXO, respectively. Discussion and conclusions: 1-The positive correlation of the number of EXO in PB and BM samples in MM and MGUS patients may support the use of EXO as liquid biopsies for biomarkers of BM disease, as a less invasive method. 2-MM patients have higher total exosomal protein cargo in PB when compared to MGUS patients and HD and this finding is particularly striking in patients with extramedullary disease and more aggressive forms of MM. The longitudinal evaluation in 2 different time-points (T1 and T2) suggests a correlation between EXO protein load and response to treatment, to be confirmed in a larger cohort. Our work will further evaluate the profile of the proteins included in these EXO and its roles on disease progression, response to treatment and micro environment modification.

  • Characterization of Circulating and Bone Marrow Derived Exosomes in Multiple Myeloma Patients

    by Bruna Velosa Ferreira, Paulo Lucio, Manuel Neves, Antonio Parreira, Bruno Costa-Silva, Cristina Joao

    Background: Multiple myeloma (MM) is characterized by clinical and biological heterogeneity, translating to variable outcome. High International Staging System (ISS), high risk cytogenetics, elevated LDH, poor response to novel drugs or extramedullary-disease (EMD) are associated to poor prognosis. Exosomes (EXO) are extra vesicular particles implicated in intercellular communication. Exosomal cargo has recently been studied as prognostic factors in cancer. MM-EXO may act as biomarkers of disease aggressiveness and potentially be used for better stratification of high risk disease in the clinical setting as liquid biopsies. Aims: To characterize peripheral blood (PB) and bone marrow aspirates (BM) EXO in MM and MGUS patients versus healthy donors (HD) and to analyze its potential use as a prognostic biomarker. Methods: EXO were isolated from PB and BM samples by ultracentrifugation. EXO protein quantity (EXOcargo) was determined by the ratio between total quantity of proteins and the total number of exosomes. Comparisons among groups of patients (MM, MGUS) and HD were made regarding EXO total protein cargo (PB and BM). Results: MM patients revealed 5x times higher EXOcargo in PB (ug/EXO) when compared to MGUS patients (p=0.007, n=15 MM and n=8 MGUS); MM median 2.34 (1.08-6.5) ug/EXO versus MGUS median 0.51 (0.29-1.04) ug/EXO. There was no differences regarding the EXOcargo between the MGUS and HD (n=6, HD median 0.88 (0.57-1.83)ug/EXO). In BM, MM EXOcargo was also higher than in MGUS: MM 2.09 (0.49-3.85)ug/EXO versus MGUS 0.53 (0.21-0.831)ug/EXO. Analyzing the patients with higher EXOcargo, we found that patients with EMD (n=4) are among the ones with higher circulating exosomal protein cargo (median 5.76 (4.36-7.95). A positive correlation in EXOcargo between PB and BM in MM and MGUS (Spearman r=0.85; p< 0.0001) was found. We also studied circulating EXOcargo at response evaluation (T2) compared to EXOcargo before MM treatment (T1): patients with deeper response had significant lower EXOcargo (CR T2 median 0.85 (0.65-1.35) pConclusion: 1-The positive correlation of the exosomal protein cargo in PB and BM samples may be a reflection of the BM compartment and potentially supports the use of EXO as liquid biopsies for biomarkers of BM disease, in a less invasive method. 2-MM patients have higher circulating exosomal protein cargo in PB when compared to MGUS patients and HD. 3- Patients with extramedullary disease and more aggressive forms of multiple myeloma have a higher exosomal cargo in the PB and this might be related to different biological features of the disease. The longitudinal evaluation in 2 different time-points suggests a correlation between EXO protein cargo and response to treatment, to be confirmed in a larger cohort.


  • ACCURACY OF SEVERITY SCORES IN RISK STRATIFICATION OF INTERNAL MEDICINE WARD PATIENTS

    by Ana Abreu, Sara Augusto, Filipa Gandara, Inês Araújo, Rosa Cardiga, Ricardo Ferreira, Marisa Alface, Margarida Proença, Daniel Romeira, Carolina Carvalho, et al.